Treatment strategies

CROI 2021: Dolutegravir with recycled tenofovir and lamivudine performs well second-line: primary results from the NADIA trial

Baseline NNRTI resistance linked to poorer response to first-line dolutegravir in the ADVANCE study      

Dolutegravir non-inferior to efavirenz at week 96 in the NAMSAL study but associated with substantial weight gain

Switching from efavirenz- to dolutegravir-based ART second-line achieved good rates of suppression: first results from the VISEND study

Early drugs being studied for COVID-19

Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution

Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study

bNAb research at CROI 2019: vaccine, prevention, treatment and cure…

Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies

Same-day ART is effective in San Francisco Rapid-ART clinic

Viral reservoir can explain persistent low level viraemia with good adherence on ART

Dolutegravir non-inferior to low dose efavirenz in real-life African study conducted in Cameroon  

Dual bNAb maintains viral suppression for median 21 weeks off-ART

Dolutegravir monotherapy: still no longer recommended in either research or clinical practice

Once-daily reduced dose darunavir/ritonavir (400 mg/100 mg) is non-inferior to twice-daily lopinavir/ritonavir in South African switch study  

M184V mutation associated with increased risk of viral blip but not viral failure with 3TC-based dual therapy

Early ART is not associated with a higher risk of HIV drug resistance

Dolutegravir-based dual therapy as switch option in multiple studies

Switch study shows F/TAF non-inferior to continuing abacavir/3TC

Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

Immune-based therapy canakinumab reduces inflammatory markers in HIV positive people on ART

Increased risk of IRIS with integrase inhibitors reported in two studies

Dolutegravir monotherapy studies halted due to integrase resistance: dual therapy studies continue

Simplifying HIV treatment: dual therapy works but monotherapy with either boosted-PIs or dolutegravir does not

Atripla three days a week for two years: pilot switch study reports undetectable viral load with better bone, kidneys and sleep

Four day a week ART: sub-optimal drug levels but few virological failures

ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms

CD4:CD8 ratio is more sensitive marker of risk than CD4 counts in analysis from START study

Treatment in primary HIV infection is significantly more likely to normalise CD4:CD8 ratio

Further results using dolutegravir monotherapy: urgent need for controlled studies

Potential economic impact of dolutegravir/3TC dual therapy

First-line ART with dolutegravir plus 3TC: 24-week early results

Achieving viral suppression with HIV multi-drug resistance: peg-interferon and valaciclovir as part of rescue therapy

Four reasons IAS 2015 will be a milestone HIV conference: a personal view

Starting HIV treatment at high CD4 counts protects against both AIDS and non-AIDS events: overall and in subgroup analyses of START study

The option for same day antiretroviral therapy on diagnosis: the future model for HIV care

Low dose boosted atazanavir is non-inferior to standard dose in Thai treatment optimisation study: LASA

HPTN 052: no HIV transmissions on effective ART but only limited data on viral failure and drug resistance

Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 counts >500

Weekend-off ART is non-inferior to continuous ART in young people taking efavirenz-based regimens: results from BREATHER study

Gender differences in use of cardiovascular disease-related interventions: D:A:D study

Higher ART coverage is associated with lower HIV infection rates in a multi-country analysis

No difference in overall anaemia rate with reduced dose AZT

Fit for purpose: treatment optimisation 2014

50% of UK seroconverters start ART within 1.4 years of infection: treating during primary infection should be a patient choice

PIVOT study: further analysis from five-year PI/r monotherapy strategy study

Hospitalisation among elite controllers

Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study

Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r

Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257

NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs

Southern African treatment guidelines retain CD4 threshold of 350 for starting ART (2013)

Executive summary and research policy recommendations

Retrofitting for purpose: treatment optimisation 2013

The tuberculosis treatment pipeline

Why the “when to start” question is complex and informed by limited evidence: a response to Dr Myron Cohen

START study increases sample size: additional 600 participants to be older than 35

Treatment in seroconversion maintains HIV specific immune responses similar to long term slow progressors

Monitoring treatment in resource limited settings: results from PHPT-3 and Stratall ANRS12110/ESTER trials

DART: high rates of viral suppression after five years and a single CD4 test with a threshold of 250 cells/mm3 could reduce unnecessary switching

Lopinavir/r monotherapy used as second-line therapy in resource-limited settings

Dose optimisation: 50 mg ritonavir-boosting, 3TC dosing and raltegravir once-daily

Switching boosted-PIs to raltegravir

Scaling up: what to do first?

Tablets more acceptable than syrups in the ARROW trial

Post navigation